

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2547816/shadia-a-galal-publications-by-citations.pdf>
Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19 papers	715 citations	11 h-index	22 g-index
22 ext. papers	788 ext. citations	4.7 avg, IF	3.42 L-index

#	Paper	IF	Citations
19	Synthesis of potent antitumor and antiviral benzofuran derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009 , 19, 2420-8	2.9	246
18	New transition metal ion complexes with benzimidazole-5-carboxylic acid hydrazides with antitumor activity. <i>European Journal of Medicinal Chemistry</i> , 2009 , 44, 1500-8	6.8	99
17	Design, synthesis and molecular docking study of novel quinoxalin-2(1H)-ones as anti-tumor active agents with inhibition of tyrosine kinase receptor and studying their cyclooxygenase-2 activity. <i>European Journal of Medicinal Chemistry</i> , 2014 , 86, 122-32	6.8	78
16	Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives. <i>European Journal of Medicinal Chemistry</i> , 2011 , 46, 327-40	6.8	50
15	Synthesis and antitumor activity of novel benzimidazole-5-carboxylic acid derivatives and their transition metal complexes as topoisomerase II inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2010 , 45, 5685-91	6.8	40
14	Novel antiviral benzofuran-transition metal complexes. <i>European Journal of Medicinal Chemistry</i> , 2010 , 45, 3035-46	6.8	33
13	Design, synthesis and structure-activity relationship of novel quinoxaline derivatives as cancer chemopreventive agent by inhibition of tyrosine kinase receptor. <i>European Journal of Medicinal Chemistry</i> , 2013 , 69, 115-24	6.8	32
12	Synthesis and docking studies of novel antitumor benzimidazoles. <i>Bioorganic and Medicinal Chemistry</i> , 2012 , 20, 6989-7001	3.4	31
11	Part I: Design, synthesis and biological evaluation of novel pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors with studying their activities alone and in combination with genotoxic drugs. <i>European Journal of Medicinal Chemistry</i> , 2017 , 134, 392-405	6.8	23
10	Synthesis and studying the antitumor activity of novel 5-(2-methylbenzimidazol-5-yl)-1,3,4-oxadiazole-2(3H)-thiones. <i>European Journal of Chemistry</i> , 2010 , 1, 67-72	0.6	22
9	Part II: New candidates of pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018 , 144, 859-873	6.8	14
8	New benzimidazoles and their antitumor effects with Aurora A kinase and KSP inhibitory activities. <i>Archiv Der Pharmazie</i> , 2015 , 348, 475-86	4.3	11
7	Part III: Novel checkpoint kinase 2 (Chk2) inhibitors; design, synthesis and biological evaluation of pyrimidine-benzimidazole conjugates. <i>European Journal of Medicinal Chemistry</i> , 2018 , 146, 687-708	6.8	11
6	Different synthetic routes to 4-(1H-benzo[d]imidazol-2-yl)aniline. <i>Research on Chemical Intermediates</i> , 2013 , 39, 2917-2923	2.8	8
5	Novel benzimidazo[2,1-c][1,4]thiazinone derivatives with potent activity against HSV-1. <i>Archiv Der Pharmazie</i> , 2011 , 344, 255-63	4.3	7
4	Synthesis, Characterization, and Cytotoxic Activity on MCF-7 Cell Line of Some Novel Metal Complexes With Substituted Benzimidazole Ligands. <i>Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry</i> , 2013 , 43, 46-56		5
3	Synthesis of (benzimidazol-2-yl)aniline derivatives as glycogen phosphorylase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016 , 24, 5423-5430	3.4	3

- | | | | |
|---|--|-----|---|
| 2 | Design, synthesis, and biological evaluation of novel benzimidazole derivatives as sphingosine kinase 1 inhibitor. <i>Archiv Der Pharmazie</i> , 2021 , 354, e2100080 | 4.3 | 1 |
| 1 | Design and synthesis of new pyrazolylbenzimidazoles as sphingosine kinase-1 inhibitors. <i>Medicinal Chemistry Research</i> , 2021 , 30, 1614-1634 | 2.2 | 1 |